Nilotinib, a novel, selective BCR-ABL inhibitor, fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib. Nilotinib is not only more potent than imatinib against wild-type BCR-ABL (IC50 < 30nM), but also significantly active against 32/33 imatinib-resistant BCR-ABL mutants.
| Product | Size | List | Your Price | Qty | Ext Price | ||||
|---|---|---|---|---|---|---|---|---|---|
| Subtotal: | Subtotal: | ||||||||
| Subtotal: | Subtotal: | ||||||||
| Total Coupon Savings: | Total Coupon Savings: | () | |||||||
| Your cart is currently empty. | |||||||||
| - Coupon Code | |||||||||
We accept the following payment methods as well as pay-by-invoice.
TDS
NCBI
UniProt
Tech Support
Customer Service
